Lilly currently has the richest mid-to-late stage pipeline in its history, but we know we cannot deliver innovation on our own. The research-based pharmaceutical industry continuously invests in R&D, but Europe is losing its competitiveness in the fight for R&D investments. We are working to promote policies that aim to speed up the development of better and safer medicines for patients.
That's why we are active participants in the Innovative Medicines Initiative, a unique partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The aims of the Innovative Medicines Initiative are to support the faster discovery and development of better medicines for patients; and enhance Europe's competitiveness by ensuring that its biopharmaceutical industry remains a dynamic high-technology sector. Lilly is an active participation in some 19 projects for diabetes, neuroscience and oncology, investing more than €20m.